Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'RNAi' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
RNAi Technologies, Markets and Companies |
March 2010 | £2310 | 100 % |
|
RNA Interference Markets |
December 2008 | £2245 | 100 % |
|
Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
June 2007 | £1495 | 97 % |
|
Future of RNAi Therapeutics, The Drug Pipelines and Prospects |
September 2008 | £1995 | 97 % |
|
Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
July 2009 | £945 | 95 % |
|
RNAi, siRNA, microRNA: Industry Background Report List of Companies |
October 2005 | £295 | 94 % |
|
RNAi/MicroRNA 2007 |
February 2007 | £2350 | 35 % |
|
RNAi Therapeutics 2008 |
November 2007 | £2350 | 30.1 % |
|
RNA Interference for Drug R&D Applications, Alliances, Companies and WW Market to 2011 |
July 2007 | £1715 | 26.6 % |
|
Drug Discovery Technologies A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 20 % |
|
Alnylam Pharmaceuticals, Inc - Financial and Strategic Analysis Review |
June 2009 | £83 | 20 % |
|
Worldwide Biotech June 2005 |
June 2005 | £17 | 19.6 % |
|
Nastech Pharmaceutical Company Inc - SWOT Analysis SWOT Analysis |
March 2009 | £44 | 13 % |
|
RNA therapy: the next big thing after monoclonal antibodies? |
October 2008 | £2640 | 12.25 % |
|
Drug Delivery Systems US Market Outlook, Advances for Pharma, Biotech & Medical Devices |
September 2006 | £1515 | 12 % |
|
MDRNA, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 12 % |
|
Alfacell Corporation - Financial and Strategic Analysis Review |
April 2009 | £83 | 11 % |
|
High-Content Analysis 2007 |
April 2007 | £1540 | 10.85 % |
|
Drug Discovery Tools for High-Content Analysis |
July 2007 | £1320 | 10.5 % |
|
IT Software Tools for Life Science and Drug Discovery Bioscience, Biotechnology, Pharmaceutical Company and Institute's IT Software Tools, Strategy, and WW Market Outlook |
June 2009 | £1515 | 10.5 % |
|
Cell-Based Assays for Drug Discovery |
August 2009 | £2245 | 10.15 % |
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
July 2007 | £1999 | 10.15 % |
|
MicroRNAs Commercial Products on the Horizon |
March 2008 | £745 | 8.75 % |
|
Translational Medicine In Biopharmaceutical R&d Enabling R&d Optimization And Early Detection Of Potential Failures |
October 2007 | £1495 | 7.7 % |
|
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
December 2006 | £1325 | 7.7 % |
|
Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
January 2007 | £1320 | 7.7 % |
|
Gene Therapy Worldwide Market Challenges & Opportunities |
November 2009 | £1980 | 7.35 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2115 | 7.35 % |
|
M&A trends in Pharma |
October 2008 | £3965 | 7.35 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 6.65 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1850 | 5.95 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1650 | 5.95 % |
|
Drug Delivery to CNS |
March 2010 | £1850 | 5.95 % |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 | 5.95 % |
|
Drug Targets for Breast Cancer |
January 2006 | £1095 | 5.95 % |
|
Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma |
February 2010 | £2310 | 5.95 % |
|
Animal Biotechnology Technologies, Markets and Companies |
March 2010 | £1650 | 5.6 % |
|
RNA Interference Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £895 | 5.5 % |
|
Cytogenetics Technologies, Markets and Companies |
March 2010 | £1455 | 5.25 % |
|
Molecular Diagnostics Markets |
September 2008 | £2245 | 4.9 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 4.55 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 4.55 % |
|
Intranasal Drug Delivery US Market Trends & Analysis |
November 2009 | £1980 | 4.55 % |
|
Nanotechnology in Health Care to 2009 |
May 2005 | £2775 | 4.2 % |
|
Biotech Drug Delivery Systems Key Company Intelligence & Market Outlook to 2012 |
February 2007 | £1299 | 4.2 % |
|
Genomics World Markets |
May 2008 | £2245 | 4.2 % |
|
Decoding Big Pharma's R&D Strategy in Oncology |
September 2007 | £1755 | 4.2 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 4.2 % |
|
Winning R&D Productivity Strategies Exploiting innovation, licensing and outsourcing opportunities |
October 2006 | £1495 | 4.2 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1650 | 4.2 % |
|
Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
January 2009 | £945 | 4.2 % |
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £2970 | 3.85 % |
|
Molecular Diagnostics Major World Markets |
February 2007 | £2640 | 3.5 % |
|
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies |
July 2007 | £945 | 3.5 % |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1980 | 3.15 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 3.15 % |
|
Global Clinical Trial Business Report & Analysis 2008-2018 |
July 2008 | £1499 | 2.8 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 2.8 % |
|
Medical Nanotechnology Markets |
September 2008 | £2245 | 2.45 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 2.1 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2310 | 1.4 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 1.4 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 1.4 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 1.4 % |
|
Alzheimer's disease |
March 2010 | £2115 | 1.4 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 1.4 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 1.4 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2640 | 1.05 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 1.05 % |
